Oral Dydrogesterone vs. Vaginal Micronized Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer
Not Applicable
- Conditions
- ART
- Interventions
- Registration Number
- NCT03832699
- Lead Sponsor
- Wolfson Medical Center
- Brief Summary
The current trial is intended to assess the efficacy of oral versus vaginal progesterone for luteal support in frozen IVF cycles.
- Detailed Description
Progesteron is used for luteal phase support in IVF cycles. Progesterone can be administered vaginally and orally. Duphaston is an oral progesterone drug, which has recentlly been proven effective in fresh cycle IVF. Yet, less is known regarding its efficacy in frozen cycle IVF. Thus, the objective of our trial is to compare the efficacy of vaginal and oral progesterone in frozen IVF cycles.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 100
Inclusion Criteria
- Ages 18-39
- Modified natural cycle (induction of ovulation with HCG)
- Consent to participation
Exclusion Criteria
- None
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Oral progesterone Dydrogesterone 10 MG - Vaginal progesterone Endometrin 100Mg Vaginal Insert -
- Primary Outcome Measures
Name Time Method Live birth rate Up to 9 months Birth of a live infant after 24 weeks gestation
- Secondary Outcome Measures
Name Time Method Clinical pregnancy rate Outcome assesed 6-7 weeks following treatment Viable pregnancy as demonstrated by ultrasound
Implantation rate Outcome assessed 6-7 weeks following treatment Number of gestational sacs divided by number of embryos transferred (percentage)
Trial Locations
- Locations (1)
Edith Wolfson Medical Center
🇮🇱Holon, Israel